The Role of Community Health Centers in Addressing the Opioid Epidemic

Issue Brief
  1. Seth, P., Scholl, L., Rudd, R. A., & Bacon, S. (2018). Overdose Deaths Involving Opioids, Cocaine, and Psychostimulants-United States, 2015-2016. MMWR. Morbidity and Mortality Weekly Report, 67(12), 349-358. https://www.cdc.gov/mmwr/volumes/67/wr/mm6712a1.htm?s_cid=mm6712a1_w#T1_down

    ← Return to text

  2. Rosenbaum, S., Tolbert, J., Sharac, J., Shin, P., Gunsalus, R. & Zur, J. (2018). Community Health Centers: Growing Importance in a Changing Health Care System. Kaiser Family Foundation. https://www.kff.org/medicaid/issue-brief/community-health-centers-growing-importance-in-a-changing-health-care-system/

    ← Return to text

  3. Julia Zur and Jennifer Tolbert, “The Opioid Epidemic and Medicaid’s Role in Facilitating Access to Treatment,” Kaiser Family Foundation, accessed June 2018, https:/”www.kff.org/medicaid/issue-bief/the-opioid-epidemic-and-medicaids-role-in-facilitating-access-to-treatment/.

    ← Return to text

  4. “The Opioid Epidemic and Medicaid’s Role in Treatment: A Look at Changes Over Time,” Kaiser Family Foundation,” accessed June 2018, https://www.kff.org/slideshow/the-opioid-epidemic-and-medicaids-role-in-treatment-a-look-at-changes-over-time/

    ← Return to text

  5. “Status of State Action on the Medicaid Expansion Decision,” accessed June 2018, https://www.kff.org/health-reform/state-indicator/state-activity-around-expanding-medicaid-under-the-affordable-care-act.

    ← Return to text

  6. Health Resources and Services Administration, “Uniform Data System: Reporting Instructions for 2016 Health Center Data,” (p. 54), accessed June 2018, https://www.bphc.hrsa.gov/datareporting/reporting/2016udsreportingmanual.pdf.

    ← Return to text

  7. Health Resources and Services Administration, “2010 Health center data: National data,” accessed June 2018, https://bphc.hrsa.gov/uds/view.aspx?q=tall&year=2010&state; Health Resources and Services Administration, “2016 health center data: National data,” accessed June 2018, https://bphc.hrsa.gov/uds/view.aspx?q=tall&year=2016&state=.

    ← Return to text

  8. “Medical providers treating patients with substance use diagnoses remain reported on Lines 1 through 10 (p. 54).” “Because substance abuse is also seen as a mental health diagnosis, it is permissible to count the visit under mental health (p. 63).” Health Resources and Services Administration, “Uniform Data System: Reporting Instructions for 2016 Health Center Data,” accessed June 2018, https://www.bphc.hrsa.gov/datareporting/reporting/2016udsreportingmanual.pdf.

    ← Return to text

  9. Substance Abuse and Mental Health Services Administration, “Medication-Assisted Treatment (MAT)” https://www.samhsa.gov/medication-assisted-treatment (accessed June 4, 2018).

    ← Return to text

  10. Rosenbaum, S., Tolbert, J., Sharac, J., Shin, P., Gunsalus, R. & Zur, J. (2018). Community Health Centers: Growing Importance in a Changing Health Care System. Kaiser Family Foundation. https://www.kff.org/medicaid/issue-brief/community-health-centers-growing-importance-in-a-changing-health-care-system/

    ← Return to text

  11. Substance Abuse and Mental Health Services Administration, “Medication-Assisted Treatment (MAT)” https://www.samhsa.gov/medication-assisted-treatment (accessed June 4, 2018).

    ← Return to text

  12. Colleen M. Grogan, et al., “Survey Highlights Differences in Medicaid Coverage for Substance Use Treatment and Opioid Use Disorder Medications,” Health Affairs 35, no. 12 (Dec. 2016):2289-2296, http://content.healthaffairs.org/content/35/12/2289.full

    ← Return to text

  13. Kathleen Gifford et al., Medicaid Moving Ahead in Uncertain Times: Results from a 50-State Medicaid Budget Survey for State Fiscal Years 2017 and 2018,” Kaiser Family Foundation, accessed June 2018, https://www.kff.org/medicaid/report/medicaid-moving-ahead-in-uncertain-times-results-from-a-50-state-medicaid-budget-survey-for-state-fiscal-years-2017-and-2018/.

    ← Return to text

  14. Ibid

    ← Return to text

  15. Office of Management and Budget, “Efficient, Effective, Accountable: An American Budget,” accessed June 2018, https://www.whitehouse.gov/wp-content/uploads/2018/02/budget-fy2019.pdf.

    ← Return to text

  16. Substance Abuse and Mental Health Services Administration, “Buprenorphine Waiver Management,” https://www.samhsa.gov/programs-campaigns/medication-assisted-treatment/training-materials-resources/buprenorphine-waiver (accessed June 4, 2018).

    ← Return to text

  17. Health Resources and Services Administration, “Electronic Health Record Capabilities and Quality Recognition: National data,” accessed June 2018, https://bphc.hrsa.gov/uds/datacenter.aspx?q=tehr&year=2016&state=&fd=.

    ← Return to text

  18. U.S. Congress, Senate, Comprehensive Addiction and Recovery Act of 2016, S.524, 114th Congress, https://www.congress.gov/114/plaws/publ198/PLAW-114publ198.pdf.

    ← Return to text

  19. Heide Jackson et al., “Cost Effectiveness of Injectable Extended Release Naltrexone Compared to Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence,” Substance Abuse 36, no. 2 (2015):226-231, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470733/

    ← Return to text

  20. Rosenbaum, S., Tolbert, J., Sharac, J., Shin, P., Gunsalus, R. & Zur, J. (2018). Community Health Centers: Growing Importance in a Changing Health Care System. Kaiser Family Foundation. https://www.kff.org/medicaid/issue-brief/community-health-centers-growing-importance-in-a-changing-health-care-system/

    ← Return to text

  21. Substance Abuse and Mental Health Services Administration, An Introduction to Extended-Release Injectable Naltrexone for the Treatment of People with Opioid Dependence (Rockville, MD: US Department of Health and Human Services, 2012), https://www.integration.samhsa.gov/Intro_To_Injectable_Naltrexone.pdf

    ← Return to text

  22. Substance Abuse and Mental Health Services Administration, Report to Congress on the Nation’s Substance Abuse and Mental Health Workforce Issues (Rockville, MD: US Department of Health and Human Services, January 2013), https://store.samhsa.gov/shin/content/PEP13-RTC-BHWORK/PEP13-RTC-BHWORK.pdf.

    ← Return to text

  23. “The Opioid Epidemic and Medicaid’s Role in Treatment: A Look at Changes Over Time,” Kaiser Family Foundation,” accessed June 2018, https://www.kff.org/slideshow/the-opioid-epidemic-and-medicaids-role-in-treatment-a-look-at-changes-over-time/

    ← Return to text

  24. Julia Zur and Jennifer Tolbert, “The Opioid Epidemic and Medicaid’s Role in Facilitating Access to Treatment,” Kaiser Family Foundation, accessed June 2018, https://www.kff.org/medicaid/issue-bief/the-opioid-epidemic-and-medicaids-role-in-facilitating-access-to-treatment/.

    ← Return to text

  25. U.S. Department of Health and Human Services. “HHS awards $94 million to health centers to help treat the prescription opioid abuse and heroin epidemic in America,” accessed June 5, 2018, https://www.hhs.gov/hepatitis/blog/2016/03/17/hhs-awards-94-million-to-health-centers-to-help-treat-the-prescription-opioid-abuse-and-heroin-epidemic-in-america.html

    ← Return to text

  26. U.S. Department of Health and Human Services. “HRSA awards $200 million to health centers nationwide to tackle mental health and fight the opioid overdose crisis,” accessed June 5, 2018, https://www.hhs.gov/about/news/2017/09/14/hrsa-awards-200-million-to-health-centers-nationwide.html

    ← Return to text

  27. U.S. Department of Health and Human Services. “FY 2018 expanding access to quality substance use disorder and mental health services (SUD-MH) supplemental funding technical assistance (HRSA-18-118),” accessed July 10, 2018, https://bphc.hrsa.gov/programopportunities/fundingopportunities/sud-mh/index.html

    ← Return to text

  28. Substance Abuse and Mental Health Services Administration, “Naloxone” https://www.samhsa.gov/medication-assisted-treatment/treatment/naloxone (accessed June 4, 2018).

    ← Return to text

  29. “States Reporting Medicaid FFS Pharmacy Benefit Management Strategies for Naloxone in Place,” Kaiser Family Foundation, accessed June 2018, https://www.kff.org/medicaid/state-indicator/states-reporting-medicaid-ffs-pharmacy-benefit-management-strategies-for-naloxone-in-place

    ← Return to text

  30. Ibid

    ← Return to text

  31. Centers for Disease Control and Prevention, “What States Need to Know about PDMPs,” https://www.cdc.gov/drugoverdose/pdmp/states.html (accessed June 4, 2018).

     

    ← Return to text

Topics

Tags

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.